FC-L
H
Endogenous
60
Rabbit IgG
#P43628
3804
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Flow Cytometry (Live) | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala173 of human KIR2DL3 protein.
Background
Killer cell immunoglobulin-like receptors (KIRs) are type 1 transmembrane glycoproteins expressed by natural killer (NK) cells and subsets of CD4, CD8, and γδ T cells (1-5). Analogous to the diversity of their human leukocyte antigen class I (HLA class I) ligands, the KIR genes are polymorphic and the content of the KIR gene cluster varies among haplotypes, although several "framework" genes are found in all haplotypes (6,7). The KIR proteins are characterized by the number of extracellular immunoglobulin-superfamily domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain (8-10). KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM) (10), while KIR proteins with the short cytoplasmic domain lack an ITIM and instead transduce activating signals (11,12). KIR proteins play an important role in the regulation of the immune response. Combinations of KIR and HLA class I variants influence susceptibility to autoimmunity and infectious disease, as well as outcomes of haematopoietic stem cell transplantation (12-14).
KIR2DL3, also referred to as CD158b, interacts with HLA-C alleles (HLA-Cw1, HLA-Cw3, and HLA-Cw7). Upon receptor ligand interaction, KIR2DL3 inhibits the activity of NK cells thus preventing target cell lysis (15-17).
- Young, N.T. et al. (2001) J Immunol 166, 3933-41.
- Battistini, L. et al. (1997) J Immunol 159, 3723-30.
- Björkström, N.K. et al. (2012) Blood 120, 3455-65.
- Remtoula, N. et al. (2008) J Immunol 180, 2767-71.
- Béziat, V. et al. (2017) Immunology 150, 248-264.
- Uhrberg, M. et al. (1997) Immunity 7, 753-63.
- Shilling, H.G. et al. (2002) J Immunol 168, 2307-15.
- Fan, Q.R. et al. (2001) Nat Immunol 2, 452-60.
- Boyington, J.C. et al. (2000) Nature 405, 537-43.
- Vivian, J.P. et al. (2011) Nature 479, 401-5.
- Stewart, C.A. et al. (2005) Proc Natl Acad Sci USA 102, 13224-9.
- Ivarsson, M.A. et al. (2014) Front Immunol 5, 184.
- Kulkarni, S. et al. (2008) Semin Immunol 20, 343-52.
- Martin, M.P. and Carrington, M. (2013) Immunol Rev 254, 245-64.
- Colonna, M. et al. (1993) Proc Natl Acad Sci U S A 90, 12000-4.
- Winter, C.C. et al. (1998) J Immunol 161, 571-7.
- Moesta, A.K. et al. (2008) J Immunol 180, 3969-79.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
FC-L: Flow Cytometry (Live)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专